, Tracking Stock Market Picks
Enter Symbol:

up 2,138.13 %

JAZZ PHARMA INC (JAZZ) rated Buy with price target $11 by Jefferies & Co

Posted on: Wednesday,  Dec 9, 2009  8:25 AM ET by Jefferies & Co

Jefferies & Co rated Buy JAZZ PHARMA INC (NASDAQ: JAZZ) on 12/09/2009, when the stock price was $7.63.
Since then, JAZZ PHARMA INC has gained 2138.14% as of 11/25/2015's recent price of $170.77.
If you would have followed this Jefferies & Co's recommendation on JAZZ, you would have gained 2138.13% of your investment in 2177 days.

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to meet unmet medical needs in neurology and psychiatry. The marketed products and late-stage product candidate of the Company include Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) extended-release capsules and JZP-6 (sodium oxybate). The other product candidates in clinical development are JZP-8 (intranasal clonazepam), being developed for the treatment of recurrent acute repetitive seizures in epilepsy patients who continue to have seizures while on stable anti-epileptic regimens, JZP-4 (sodium and calcium channel antagonist), being developed for the treatment of epilepsy and bipolar disorder, and JZP-7 (ropinirole gel), being developed for the treatment of restless legs syndrome.

Our focus on growing and mid-sized companies enables us to identify unique investment ideas, which can make the difference in a tough market. Jefferies' research effort covers U.S. & International equity, high yield, convertibles, investment grade fixed income and post-reorganization securities, as well as special situations and quantitative research. The more than 120-person team of research professionals covers over 1,200 companies in more than 40 industries worldwide. Our analysts focus on identifying emerging industry themes and dig deeper to provide in-depth, thought provoking, objective research. Our analysts use a variety of quantitative and qualitative tools, integrating field analysis, proprietary channel checks and ongoing dialogue with the managements of the companies they cover. We utilize the latest technologies to deliver a research product that is timely, differentiated, and tailored to each customer's needs. Regular client access to companies and their management teams is provided through a wide variety of Jefferies hosted industry conferences, company management meetings and on-site tours.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/9/2009 8:25 AM Buy
7.63 11.00
as of 12/31/2009
1 Week up  166.58 %
1 Month up  188.59 %
3 Months   
1 YTD up  188.59 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy